Exogenous GLP-1 improves gastric compliance in a dose-dependent manner (Schirra et al., 2002), reduces the frequency and amplitude of gastric antrum and duodenum contraction, inhibits the contractile force of gastric antrum and duodenum, increases pyloric tension, and stimulates pyloric tetanic and phase motion (Schirra et al., 2000)
[5] It acts through GHS-R1a / the ghrelin pathway
These agonists not only enhance GLP-1 release but also suppress the expression of pro-inflammatory cytokines, including IL-2, IL-17a, interferon-, and TNF- (Yusta et al., 2015)
Oncology Central
For More Information: See my other blogs on COVID-19 prevention and protection Order pharmaceutical grade supplements Check out my books Viral Immunity and Beating the Flu Sign up for my Friday Q&A on natural health